07:32 AM EDT, 08/08/2025 (MT Newswires) -- GSK (GSK) said Friday that it will receive $370 million from the mRNA patent settlement deal between CureVac ( CVAC ) and BioNTech (BNTX).

The payment is related to an existing license agreement with CureVac ( CVAC ) and GSK said it will also be entitled to a 1% royalty on BioNTech and Pfizer's ( PFE ) US sales of influenza, COVID-19 and related combination mRNA vaccine products from the start of 2025.

In addition, GSK said it will receive an additional $130 million in cash and a 1% royalty if BioNTech completes its acquisition of CureVac ( CVAC ), which will also settle the companies' mRNA patent litigation outside of the US. The royalty is applicable to BioNTech and Pfizer's ( PFE ) future sales outside of the US, said the the company.

As part of the deal, GSK will also benefit from reduced milestones and lower royalties payable on its sales of mRNA influenza, COVID-19, and combination products outside of the US, according to the statement.